June Off to a Poor ...
Health Care: Drugs
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$2.82 -0.15 | -5.05%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.82 |
| 52 Week High | 4.52 |
| 52 Week Low | 1.77 |
| Avg. Daily Vol. (Mil) | 1.18 |
| Beta (3 year) | 1.10 |
| Share Related Items | |
| Mkt Cap (Mil) | 382.63 |
| Shares Out (Mil) | 135.68 |
| Float (Mil) | 94.90 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.30 |
| Current Ratio | 4.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 15.65 |
| Price/Book | 6.45 |
| Price/Cash Flow | -5.80 |
| Per Share Data | |
| Earnings | -0.53 |
| Sales | 0.18 |
| Book Value | 0.44 |
| Cash Flow | -0.49 |
| Business Summary | |
|---|---|
| Avanir Pharmaceuticals Inc. focuses on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. | |
| General Information | |
| 20 Enterprise
Suite 200 Aliso Viejo, CA 92656 |
|
| www.avanir.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 188 | |
| CEO: Keith A. Katkin | |
| Short Interest | |
| Current Month (Mil) | 23.89 |
| Previous Month (Mil) | 24.15 |
| Short Interest Ratio (Days) | 23.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -84.50 |
| Return on Investments | -112.00 |
| Profitability | |
| Gross Margin | 97.60 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with AVNR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
- Contributor5 Stocks With the Largest S...
- Usergm401
- Userparvardigar
Latest AVNR Headlines from TheStreet
- Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript) 05.17.12 | 05:05 pm
- Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 11:05 pm
- Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript 05.08.12 | 03:05 pm
- Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript 02.29.12 | 01:02 pm
- AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript 02.07.12 | 10:02 pm
- Friday's Top 10 Articles, Videos on TheStreet 01.20.12 | 02:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- AVANIR Stock Hits New 52-Week Low (AVNR) 12.14.11 | 03:12 pm
- Avanir's CEO Discusses Q4 2011 Results - Earnings Call Transcript 12.12.11 | 11:12 pm
- Biotech Stock Mailbag: 2011 Report Card 11.25.11 | 05:11 am
Press Releases for AVNR
- Avanir Pharmaceuticals To Present At Jefferies 2012 Global Healthcare Conference - PR Newswire 05.29.12 | 08:05 am
- Avanir Pharmaceuticals To Present Data At The American Academy Of Neurology Annual Meeting - PR Newswire 04.17.12 | 08:04 am
- Avanir Pharmaceuticals To Present At BioCentury Future Leaders In The Biotech Industry Conference - PR Newswire 04.10.12 | 08:04 am
- Avanir Pharmaceuticals Announces Appointment Of Rohan Palekar As Chief Commercial Officer - PR Newswire 03.16.12 | 08:03 am
- Avanir Pharmaceuticals To Participate In Two Conferences In March - PR Newswire 03.01.12 | 04:03 pm
- Avanir Pharmaceuticals To Participate In Citi 2012 Global Health Care Conference - PR Newswire 02.21.12 | 09:02 am
- Avanir Pharmaceuticals Announces Publication Of Phase III Study Results Showing Efficacy And Safety Of AVP-923 In The Treatment Of Diabetic Neuropathic Pain - PR Newswire 02.08.12 | 09:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 First Quarter Financial Results And Conference Call - PR Newswire 01.30.12 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2011 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.06.11 | 08:12 am
- Avanir Pharmaceuticals To Participate In Piper Jaffray Health Care Conference - PR Newswire 11.22.11 | 08:11 am
Partner Headlines for AVNR
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Avanir Pharmaceuticals: Limelight On The Horizon - Seeking Alpha 02.17.12 | 06:02 am
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
- Avanir - Closing Short Position - Seeking Alpha 11.27.11 | 08:11 am
- 10 Small-Cap Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 10:11 pm
- Avanir Pain Drug Should Provide Long-Term Growth - Seeking Alpha 09.30.11 | 06:09 pm
- Avanir: Congressional Inquiry Into the Pricing of Nuedexta Abandoned - Seeking Alpha 07.22.11 | 09:07 am
- Hearing Negative Chatter in Avanir Pharmaceuticals - Benzinga 06.30.11 | 01:06 pm
- Jefferies' Upadates - Benzinga 06.03.11 | 09:06 am
- Investors Should Take Notice of Congressional Questions Regarding Nuedexta Pricing - Seeking Alpha 05.27.11 | 09:05 am
